A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning

Trial Profile

A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs MGTA 456 (Primary)
  • Indications Globoid cell leukodystrophy; Metachromatic leukodystrophy; Mucopolysaccharidosis I
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 05 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 20 Sep 2017 Status changed from withdrawn prior to enrolment to not yet recruiting.
    • 22 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment with no patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top